“While the weight loss results were impressive across the group, the cost and side effects remain important barriers for long ...

Billions of dollars in annual revenue and the health of millions of patients are at stake in a drug industry battle over who ...

Mounjaro, a weekly injection, targets GIP and GLP-1 hormones to enhance insulin release and appetite regulation, aiding ...

Eli Lilly and Novo Nordisk are in a global battle for dominance in the weight loss space. BioSpace takes a look at the ...

Eli Lilly's CEO, David Ricks, reveals potential plans to manufacture the weight-loss drug Mounjaro in India as part of their global expansion.

JM Financial is bullish on Mounjaro's success in India, citing its price advantage, higher efficiency and the country's large ...

Investing in stocks remains one of the best ways to accumulate capital over long periods. Companies that can last -- and ...

Mounjaro, a weight loss drug launched by Eli Lilly in India, could be a game-changer and has been making waves lately. Here's ...

Alphabet just got a confidence boost as Analyst IMS Investment Management Services Ltd. upped its holdings by nearly 38% this ...

Eli Lilly’s Global CEO David Ricks revealed that the pharma giant might manufacture its weight-loss blockbuster, Mounjaro, in ...

Eli Lilly CEO David Ricks reveals that developing a new drug costs around $4 billion before marketing. In an exclusive ...

GLP-1 receptor agonists, originally introduced in 2006, have undergone significant advancements over the years. David Ricks, ...